Description
DESCRIPTION (provided by applicant): The objective of this program project application is to develop novel therapeutics that target CNS and peripheral reservoirs of HIV-1 replication. Under the auspices of a U19, we have identified novel small molecules that target the vif-apobec axis and that specifically inhibit vif-dependent viral replication. Structure Activity Relationship (SAR studies have identified potent analogs (IC50
| Status | Finished |
|---|---|
| Effective start/end date | 8/19/13 → 7/31/19 |
Funding
- National Institutes of Health: $1,168,508.00
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health: $1,181,526.00
- National Institutes of Health
- National Institutes of Health: $1,237,491.00
- National Institutes of Health
- National Institutes of Health: $1,194,404.00
- National Institutes of Health
- National Institutes of Health
- National Institutes of Health: $1,262,306.00
Fingerprint
HIV-1
Structure-Activity Relationship
Inhibitory Concentration 50
Antiviral Agents
Macrophages
Macaca
Therapeutics
Mutation
Viral RNA
Drug Discovery
intellectual property
Research Personnel
Viruses